Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05410379
Other study ID # MCH 2021-01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 15, 2021
Est. completion date March 15, 2023

Study information

Verified date May 2023
Source Maria Cecilia Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Atrial fibrillation (AF) is defined as a supraventricular tachyarrhythmia with uncoordinated atrial electrical activation and consequently ineffective atrial contraction. Electrocardiographic characteristics of AF include: irregularly irregular R-R intervals (when atrioventricular conduction is not impaired), absence of distinct repeating P waves, and irregular atrial activations. Different AF classifications have been proposed but, traditionally, four patterns of AF are distinguished, based on presentation, duration, and spontaneous termination of AF episodes. Paroxysmal AF, that terminates spontaneously or with intervention within 7 days of onset. Persistent AF that is continuously sustained beyond 7 days, including episodes terminated by cardioversion (drugs or electrical cardioversion) after >7 days. Long-standing persistent (continuous AF of >12 months' duration) when decided to adopt a rhythm control strategy. Permanent AF, that is accepted by the patient and physician, and no further attempts to restore/maintain sinus rhythm will be undertaken. The purpose of this study is to perform assessments of local impedance before and after cryoablation performed with the new POLAR X cryoballoon, in order to characterize the quality of the lesion and possibly to associate it with the acute success and 12 months AF recurrence-free rate.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date March 15, 2023
Est. primary completion date March 15, 2023
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Subjects indicated for the treatment of AF with the cryoablation system according to current and future Guidelines and system indications for use; 2. Subjects who are willing and capable of providing informed consent; 3. Subjects who are willing and capable of participating in all testing associated with this clinical study at an approved clinical investigational center. 4. Subjects whose age is 18 years or above, or who are of legal age to give informed consent specific to state and national law. Exclusion Criteria: 1. Any known contraindication to an AF ablation or anticoagulation, including those listed in the instructions for use; 2. Subjects with indication for treatment of AF that is not according to current and future Guidelines and system indications for use; 3. Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or any other reversible or non-cardiac cause; 4. Known or pre-existing severe Pulmonary Vein Stenosis; 5. Evidence of myxoma, LA ( left atrium) thrombus or intracardiac mural thrombus; 6. Previous cardiac surgery (e.g. ventriculotomy or atriotomy, CABG (Coronary artery bypass graft surgery ), PTCA ( Percutaneous transluminal coronary angioplasty), stent procedure) within 90 days prior to enrollment; 7. Implantable cardiac device procedures ,e.g. PM (pacemaker), ICD( implantable cardioverter defibrillators), CRT within 30 days prior to enrollment; 8. Implanted Left Atrial Appendage Closure device prior to the index procedure; 9. Interatrial baffle, closure device, patch, or patent foramen ovale (PFO) occluder; 10. Subjects with severe valvular disease OR with a prosthetic - mechanical or biological - heart valve (not including valve repair and annular rings); 11. Presence of any pulmonary vein stents; 12. Active systemic infection; 13. Vena cava embolic protection filter devices and/ or known femoral thrombus; 14. Any previous history of cryoglobulinemia; 15. History of blood clotting or bleeding disease; 16. Any prior history of documented cerebral infarct, TIA (transient ischemic attack) or systemic embolism (excluding a post-operative deep vein thrombosis (DVT)) = 180 days prior to enrollment; 17. Subjects who are hemodynamically unstable or with structural heart disease; 18. The subject is unable or not willing to complete follow-up visits and examination for the duration of the study; 19. Life expectancy = 1 year per investigator's opinion; 20. Women of childbearing potential who are, or plan to become, pregnant during the time of the study (method of assessment upon investigator's discretion); 21. Unrecovered/unresolved Adverse Events from any previous invasive Procedure; 22. Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Italy MCH Cotignola Ravenna

Sponsors (1)

Lead Sponsor Collaborator
Maria Cecilia Hospital

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary local impedance drop The primary endpoint of the study is the local impedance drop, measured as the difference between local impedance recorded by the rhythmic HDx mapping system at baseline and after PVI (pulmonary vein isolation) . For the primary endpoint assessment, impedance data will be analyzed offline and grouped per 4 anatomical segments around each pulmonary vein (PV). Absolute values of local impedance measured at baseline and after PVI, as well as local impedance drops will be also compared according to lesion success and according to the value of conventional predictors of successful cryo-lesions (e.g. TTI ( time to isolation ) < 60 s). 6 months
Secondary failure-free rate at 12 months The endpoint is the recurrence of atrial tachycardia (AT) and AF after the blanking period (3 months), as measured by means of ECG and 24h-holter. It will be evaluated by the failure-free rate at 12 months post-index procedure in each cohort. 12 months.
See also
  Status Clinical Trial Phase
Completed NCT02630914 - Medical and Surgical Hybrid Treatment of Atrial Fibrillation. N/A
Enrolling by invitation NCT05407415 - KardiaMobile ECG Monitoring Effects on Health Care Utilization and Patient Experience With Atrial Fibrillation N/A
Completed NCT04025710 - Master Study of the BIOMONITOR III and Incision and Insertion Tool (FIT OneStep) N/A
Completed NCT01119274 - EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon Phase 4
Recruiting NCT03428048 - Cardiovascular Innovation & Research Institute 's NEXUS Registry, the Whole is Greater Than the Parts.
Recruiting NCT04298723 - Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding. N/A
Completed NCT04218266 - Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications. Phase 2
Active, not recruiting NCT03732794 - AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment N/A
Active, not recruiting NCT04755283 - Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation Phase 2
Completed NCT04095559 - Characterization of Left Atrial Substrate by Comparison of Bipolar Voltage Maps With Standard Focal 4.5 mm Tip Electrode, 1 mm Ring Electrode, and Microelectrode Catheters Using InTEllaMap Orion and IntellaNav MIFI O
Recruiting NCT05712200 - Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) Phase 3
Recruiting NCT05955365 - Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation Phase 4
Recruiting NCT05294445 - From the Emergency Department Directly to Ablation of Atrial Fibrillation Study N/A
Completed NCT02513316 - Clinical Relevance of Microbleeds In Stroke N/A
Completed NCT04809922 - Accuracy of Cardiac Wearables Devices to Detect Atrial Fibrillation